Cargando…
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding kinases from phosphorylating tyrosine residues of their substrates and then block the activation of downstream signaling pat...
Autores principales: | Huang, Liling, Jiang, Shiyu, Shi, Yuankai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590700/ https://www.ncbi.nlm.nih.gov/pubmed/33109256 http://dx.doi.org/10.1186/s13045-020-00977-0 |
Ejemplares similares
-
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
por: Wen, Tingyu, et al.
Publicado: (2020) -
Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors
por: Bellantoni, Andrew J., et al.
Publicado: (2021) -
Prognostic value of spleen tyrosine kinase in human solid tumors
por: Ni, Beibei, et al.
Publicado: (2018) -
Tyrosine Kinase Inhibitors in the Treatment of Metastasised Renal Cell Carcinoma—Future or the Past?
por: Michaelis, Jakob, et al.
Publicado: (2022) -
20-Year Trends in Metabolic Syndrome Among Korean Adults From 2001 to 2020
por: Park, Dahyun, et al.
Publicado: (2023)